

**LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/ $\beta$ -Catenin Signaling [Corrigendum]**

Wang Q, Liao J, He Z, et al. *Onco Targets Ther.* 2020;13:10983–10994

The Corrigendum notice (<https://www.dovepress.com/corrigendum-lhx6-affects-erlotinib-resistance-and-migration-of-egfr-mu-peer-reviewed-article-OTT>) that was published January 12, 2021 was incorrect. The authors have advised on page 10993, Funding section, “This study was supported by grants from the Natural Science Foundation of Fujian Province (grant nos. 2017J01261 and

2016JD1488)” should have been “This study was supported by grants from the Startup Fund for Scientific Research, Fujian Medical University (grant no. 2017XQ1217), Joint Funds for the Innovation of Science and Technology, Fujian Province (grant no. 2017Y9080), and Fujian Provincial Sci & Tech Guiding Project (grant no. 2018Y0017).”

The authors apologize for this error.

**Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>